These courses are intended for internal hospital staff.

Activity Description:

The Skull Based Tumor Board brings together skull base tumor experts to discuss optimal treatments for individual patients. Complex tumors are discussed, including meningiomas, acoustic neuromas, pituitary tumors, and schwannomas. The board includes subspecialized otolaryngologists (anterior skull base, lateral skull base, head/neck surgical oncology, and facial plastic surgery), skull base and cerebrovascular neurosurgeons, radiation oncologists, neuroradiologists, and neuropathologists. 

Target Audience: 

This activity is intended for Neurosurgeons, Head & Neck Surgeons, Otolaryngologists, Rhinologists and Otologists/Neuro-Otologists

Learning Objectives: 

  • Evaluate the role of surgery within the context of multimodality care in the management of skull base malignancies.
  • Assess the relative indications for endoscopic and open skull base approaches in the management of complex skull base pathology and implement them into practice.
  • Understand the anatomical basis of various open and endoscopic skull base approaches in the management of malignant tumors of the anterior and anterolateral skull base.

Moderator:     

Andy Nemechek, MD

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

 

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose. 

Session date: 
08/02/2023 - 7:00am to 8:00am MDT
Location: 
Swedish Medical Center
501 E Hampden Ave
Pine B+C
Englewood, CO 80113
United States
  • 1.00 AMA PRA Category 1 Credit
    HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    HCA Healthcare Continental Division designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance

Please login or register to take this course.